GlobeVerge
Home / business
MARKETS
Novo Nordisk CEO defends economics of Wegovy pill as lower prices weigh on sales; shares fall
GlobeVerge has tracked this story since 4h ago.
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
GlobeSignal
Market Mover
Market-moving news like this can affect investment values and business planning.
Expand ▾
More in Finance
- Tamil Nadu Budget: State’s outstanding debt pegged at ₹10.98 lakh crore in Revised Budget Estimates
- Here's what to expect when Disney reports earnings before the bell
- Trump's deportation agenda raised prices, contracted local economies, immigration group says
- Next upgrades profit outlook again as it benefits from summer spending
GlobeSignal: A transparent, keyword-based read on this story's tone and stakes—not financial, political or safety advice. The summary above is the original publisher's excerpt, not AI-generated or rewritten by GlobeVerge. Open the original source link before acting on any story.